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SUMMARY 
BACKGROUND AND PURPOSE: Pharmacological separation of the background potassium 
currents of closely related K2P channels is a challenging problem. We previously demonstrated 
that ruthenium red (RR) inhibits TASK-3 (K2P9) but not TASK-1 (K2P3) channel. RR has been 
extensively used to distinguish between TASK currents in native cells. In the present study, we 
systematically investigate the RR sensitivity of a more comprehensive set of K2P channels. 
EXPERIMENTAL APPROACH: K
+
 currents were measured by two-electrode voltage clamp 
in Xenopus oocytes and by whole-cell patch clamp in mouse dorsal root ganglion (DRG) neurons. 
KEY RESULTS: Ruthenium red differentiates between two closely related members of the 
TREK subfamily. TREK-2 (K2P10) proved to be highly sensitive to RR (IC50=0.2 µM), whereas 
TREK-1 (K2P2) was not affected by the compound. We identified aspartate 135 (D135) as the 
target of the inhibitor in mouse TREK-2c. D135 lines the wall of the extracellular ion pathway 
(EIP), a tunnel structure through the extracellular cap characteristic for K2P channels. TREK-1 
contains isoleucine in the corresponding position. The mutation of this isoleucine (I110D) 
rendered TREK-1 sensitive to RR. The third member of the TREK subfamily, TRAAK (K2P4) is 
more potently inhibited by ruthenium violet, a contaminant in some RR preparations, than by RR. 
DRG neurons predominantly express TREK-2 and RR-resistant TREK-1 and TRESK (K2P18) 
background K
+
 channels. We detected the RR-sensitive leak K
+
 current component in DRG 
neurons. 
CONCLUSIONS AND IMPLICATIONS: We propose that RR may be useful for 
distinguishing TREK-2 from TREK-1 and other RR-resistant K2P channels in native cells. 
 
KEYWORDS: two-pore domain, potassium channel, ruthenium red, TREK2, KCNK2, 
KCNK10, TALK-1, TASK-2, THIK-1 
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ABREVIATIONS 
 
DRG dorsal root ganglion 
K2P two-pore-domain K
+
 (channel) 
RR ruthenium red 
RV ruthenium violet 
TALK TWIK-related alkaline-activated K
+
 channel 
TASK TWIK-related acid-sensitive K
+
 channel 
THIK TWIK-related halothane-inhibited K
+
 channel 
TRAAK TWIK-related arachidonic acid-activated K
+
 channel 
TREK TWIK-related K
+
 channel 
TRESK TWIK-related spinal cord K
+
 channel 
TWIK tandem of pore domains in a weakly inwardly rectifying K
+
 channel 
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INTRODUCTION 
 
Different members of the two-pore domain (K2P) K
+
 channel family show characteristic 
expression patterns, they are regulated by extraordinarily diverse mechanisms, and contribute to a 
great variety of physiological processes (Enyedi and Czirják, 2010). These channels give rise to 
similar macroscopic background (leak) potassium currents, and thus it is a challenge to 
distinguish them in whole-cell measurements. Identification of individual K2P channel types is 
also of importance because the different members of the family may prove to be therapeutic 
targets in distinct pathophysiological states (Mathie and Veale, 2007; Bittner et al., 2010). 
Pharmacological properties of K2P channels have been extensively investigated; however, the 
background K
+
 currents were typically affected by relatively nonspecific compounds (Lotshaw, 
2007). It appears to be difficult to identify highly selective inhibitors of K2P channels, perhaps 
because of the distinctive structural element, the extracellular cap, which covers the entrance of 
the ion conducting pore, and restricts the access of high molecular weight inhibitors to the 
opening (Brohawn et al., 2012; Miller and Long, 2012).   
We previously demonstrated that low micromolar concentrations of ruthenium red 
([(NH3)5Ru-O-Ru(NH3)4-O-Ru(NH3)5]Cl6) inhibit TASK-3 background K
+
 channel, whereas 
TASK-1 is not affected by the polycationic dye (Czirják and Enyedi, 2003). This observation 
proved to be useful because of the remarkably selective action of ruthenium red (RR) 
distinguishing between the two closely related TASK channels, and despite of the limited overall 
specificity of the compound. RR is known to inhibit a multitude of target proteins, most of them 
related to the transport or binding of Ca
2+
 (e.g. calcium channels and pumps, as detailed in the 
Discussion section of ref. (Czirják and Enyedi, 2003)). A negatively charged amino acid, 
glutamate 70 (E70) was established as the major determinant of TASK-3 inhibition by RR 
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(Czirják and Enyedi, 2003; Musset et al., 2006; Gonzalez et al., 2013). TASK-1 contains a 
positive lysine in the corresponding position, and the channel was rendered RR-sensitive by the 
K70E mutation, indicating that the high charge density ruthenium compound differentiated 
between the channels by electrostatic interaction on the basis of a single distinct amino acid 
residue. 
Differential sensitivity of TASK-1 and TASK-3 to RR has been extensively used to 
investigate TASK currents in adrenal glomerulosa cells (Czirják and Enyedi, 2002b), carotid 
body glomus cells (Kim et al., 2009), cardiomyocytes (Putzke et al., 2007), pulmonary artery 
smooth muscle cells (Olschewski et al., 2006), motoneurons (Berg et al., 2004; Larkman and 
Perkins, 2005), cerebellar granule neurons (Lauritzen et al., 2003; Kang et al., 2004; Aller et al., 
2005), thalamocortical relay neurons (Musset et al., 2006), and several other cell types (Berg and 
Bayliss, 2007; Deng and Lei, 2008; Weber et al., 2008; Ernest et al., 2010). We reported 
previously that in addition to TASK-3, another K2P channel, TRAAK, a member of the TREK 
subfamily, is also sensitive to RR. Whereas in the case of TASK-3 the Hill coefficient of about 1 
was in good accordance with the binding of one RR molecule simultaneously to both E70 
residues in the dimer of the subunits, the inhibition of TRAAK by RR was characterized by a Hill 
coefficient of 2, suggesting that RR inhibits TRAAK and TASK-3 by different mechanisms 
(Czirják and Enyedi, 2002a). 
In the present study we investigated a more comprehensive set of K2P channels in order to 
categorize them into RR-sensitive and RR-resistant groups, and also examined the mechanism of 
action of the inhibitor.  
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METHODS 
 
Plasmids and reagents 
 
The cloning of mouse TASK-1/2/3 (K2P3.1/K2P5.1/K2P9.1), TREK-2 (K2P10.1), TALK-1 
(K2P16.1), THIK-1 (K2P13.1) and human and mouse TRESK (K2P18.1) has been described 
previously (Czirják and Enyedi, 2006; Czirják et al., 2004). Human and mouse TRAAK (K2P4.1) 
and TREK-1 (K2P2.1), and human TREK-2 channel plasmids were kindly provided by Professor 
M. Lazdunski and Dr. F. Lesage. Drug target nomenclature conforms with British Journal of 
Pharmacology's Guide to Receptors and Channels (Alexander et al., 2013). Different mutant 
versions of these channels were produced with QuikChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA) according to the manufacturer’s instructions. For the construction of 
tandem wt/wt, wt/mutant and mutant/wt mTREK-2 channels, the TAA stop codon of the 
upstream subunit and the ATG start codon of the downstream subunit were replaced with a 
unique MunI restriction enzyme site. This introduced a two amino acid linker (glutamine and 
leucine) between the coding sequences of the concatenated subunits. 
Chemicals of analytical grade were purchased from Sigma (St. Louis, MO), Fluka 
(Milwaukee, WI ) or Merck (Whitehouse Station, NJ). Enzymes and kits for molecular biology 
applications were purchased from Ambion (Austin, TX), Thermo Scientific (Waltham, MA), New 
England Biolabs (Beverly, MA) and Stratagene. 
 
Purification of ruthenium violet 
 
Ruthenium red (RR) and ruthenium violet (RV) were dissolved in 0.1 M ammonium acetate 
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as 10 mM stock solutions, and diluted further in high [K
+
] solution before the measurement. In 
order to purify RV, we applied cation exchange chromatography using carboxy-methyl (CM) 
cellulose resin (Whatman CM52). Crude RR preparation (70 mg) was dissolved in ammonium 
acetate (AA, 10 mM, 30 ml). The solution was applied to a 1 ml CM cellulose column at a flow 
rate of 0.4 ml/min. The flowthrough was colorless, whereas the column became dark with the 
adsorbed dyes. Bulk RR was eluted by two rounds of isocratic elution (750 mM AA, 10 ml), 
followed by washing steps (50 mM AA, 20 ml). Subsequently, RV was eluted with a linear 
gradient of AA (from 50 mM to 1.5 M, in 20 ml); the major RV peak appeared between 1.2-1.4 
M. Fractions containing RV were lyophilized, immediately dissolved in 10 mM AA, and stored at 
-20 °C. The calculated molar ratio of RV/RR was increased from 0.1 to 9.5 by the purification. 
(RV concentration was calculated using the extinction coefficient ε = 311 (g/100 ml)
-1
cm
-1
 at 734 
nm (Luft, 1971), and molecular weight 751.43 g/mol (Hall and Griffith, 1980)). 
 
Animals, Xenopus oocyte microinjection, isolation of DRG neurons 
 
DRG neurons derived from six NMRI mice, purchased from Toxicoop, Budapest, Hungary. 
Mice were maintained on a 12 h light/dark cycle with free access to food and water. Animals 
were sacrificed by CO2 exposure. Xenopus oocytes were prepared, the cRNA was synthesized 
and microinjected as previously described (Czirják et al., 2004). (For the expression of the 
different channel types, 57 pg - 2.3 ng/oocyte cRNA was injected.) Fifteen frogs were used for 
the experiments. The animals were maintained in two 50 L tanks, with continuous filtering and 
water circulation through aquarium pumps at 19 °C in an air conditioned room. The frogs were 
anaesthetized with 0.1% tricaine solution and sacrificed by decerebration and pithing. All 
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treatments of the animals were conducted in accordance with state laws and institutional 
regulations. The experiments were approved by the Animal Care and Ethics Committee of 
Semmelweis University (approval ID: XIV-I-001/2154-4/2012). The results of all studies 
involving animals are reported in accordance with the ARRIVE guidelines (McGrath et al., 
2010). 
Dorsal root ganglia (DRGs) were dissected from thoracic and lumbar levels of the spinal cord 
of 40-70 day old mice. DRGs were collected in sterile PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
NaH2PO4, pH 7.4 with NaOH) at 4°C. Ganglia were incubated with gentle shaking for 30 min at 
37 °C in PBS containing 2 mg/ml collagenase (type I; Worthington, Lakewood, NJ). Then 
DMEM-F-12 containing 10 % fetal bovine serum (Lonza, Basel, Switzerland) and 100 U/ml 
penicillin-streptomycin (Sigma) was added, and gentle trituration was performed with a cut 1 ml 
plastic pipette tip for 10-15 times. Cells were centrifuged at 200 g for 5 minutes, washed three 
times with culture medium, and plated on plastic culture dishes treated with poly-L-lysine. They 
were incubated in 95% air - 5% CO2 mixture at 37 °C, and measured after 1-3 days. 
 
Two-electrode voltage clamp and patch clamp measurements 
 
Two-electrode voltage clamp experiments were performed three or four days after the 
microinjection of cRNA, as previously described (Czirják et al., 2004). Low [K
+
] solution 
contained (in mM): NaCl 95.4, KCl 2, CaCl2 1.8, HEPES 5 (pH 7.5 adjusted with NaOH). High 
[K
+
] solution contained 80 mM K
+
 (78 mM Na
+
 of the low [K
+
] solution was replaced with K
+
). 
Background K
+
 currents were measured at the end of 300 ms long voltage steps to -100 mV 
applied in every 4 s.  
DRG neurons were measured by whole-cell patch clamp at 37 °C. The low [K
+
] extracellular 
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solution contained (in mM): NaCl 140, KCl 2, MgCl2 0.5, CaCl2 2, glucose 11, HEPES 10, pH 
7.4 (adjusted with NaOH). High [K
+
] extracellular solution contained 30 mM K
+
 (28 mM Na
+
 of 
the low [K
+
] solution was replaced with K
+
). Pipettes were pulled from borosilicate glass by a P-
87 puller (Sutter Instrument Co., Novato, CA) and fire polished. Pipette resistance ranged 
between 3 and 9 MΩ when filled with the intracellular solution containing (in mM): KCl 135, 
MgCl2 2, EGTA 1, Na2ATP 2, HEPES 10, pH 7.3 (adjusted with NaOH). The pipette was 
connected to the headstage of a patch clamp amplifier Axopatch-1D (Axon Instruments, Inc., 
Foster City, CA), data were digitally sampled by Digidata 1200 (Axon Instruments), and 
analyzed by pCLAMP 10 software (Molecular Devices, Sunnyvale, CA). 
 
Statistics and calculations 
 
Data are expressed as means±S.E. Normalized dose-response curves were fitted by a 
modified Hill equation of the form y = α / (1 + (c/K1/2)
n
) + (1 - α), where c is the concentration, 
K1/2 is the concentration at which half-maximal inhibition occurs, n is the Hill coefficient, and α 
is the fraction inhibited by the treatment. Statistical significance was estimated by Student’s t test 
for independent samples, one-way ANOVA followed by Scheffe’s post hoc test or Pearson's 
product-moment correlation analysis (as indicated in the figure legends). The difference was 
considered to be significant at p<0.05. 
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RESULTS 
 
Characterization of the ruthenium red sensitivity of K2P channels: TREK-2 is potently 
inhibited by the polycationic compound 
 
Different K2P channel types were expressed in Xenopus laevis oocytes, and their sensitivity 
to the polycationic dye ruthenium red (RR, Fig. 1. A) was measured at -100 mV in 80 mM [K
+
] 
by two-electrode voltage clamp. In accordance with our previous results (Czirják and Enyedi, 
2002a), human and mouse TREK-1 (K2P2) currents were negligibly affected by the application 
of 10 µM RR (for representative recording see Fig. 1. B). Neither of our RR preparations, 
purchased from Sigma in 1996 and 2013, respectively, were effective inhibitors of TREK-1. 
RR2013 reduced human TREK-1 current only by 5.0 ± 1.9 % (n = 5), and the mouse channel 
current by 7.1 ± 2.4 % (n = 6; see hTREK-1 and mTREK-1 in Fig. 1. E). Unexpectedly, human 
and mouse TREK-2 (K2P10) currents were substantially blocked by RR, despite of the high 
amino acid sequence similarity of TREK-1 and TREK-2 channels (for representative recording 
see Fig. 1. C). Human TREK-2 was inhibited by 75.1 ± 4.2 % (n = 4), whereas its mouse 
counterpart by 90.7 ± 1.6 % (n = 6; see hTREK-2 and mTREK-2 in Fig. 1. E). RR1996 similarly 
inhibited TREK-2 as RR2013 (not shown). These data indicate that in addition to its discriminating 
effect on TASK channels, ruthenium red also distinguishes between the closely related TREK-1 
and TREK-2 members of the K2P family. 
The third member of the TREK subfamily, TRAAK (K2P4), was less inhibited by 10 µM 
RR2013 than TREK-2 (for representative recording see Fig. 1. D; 32.3 ± 2.7 % (n = 5) and 56.0 ± 
0.7 % (n = 8) inhibition for human and mouse TRAAK, respectively, Fig. 1. E). This relatively 
weak inhibition of TRAAK by RR was not anticipated, because of our own previously reported 
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data about the high sensitivity of the channel to RR (Czirják and Enyedi, 2002a), and urged us to 
investigate the reason for the apparent discrepancy between the present and previous data (see 
below). Among the other tested K2P channels, mouse TASK-3 was inhibited (Fig. 1. E) as 
reported previously (Czirják and Enyedi, 2003), whereas mTALK-1, mTASK-1, mTASK-2, 
mTHIK-1 and mTRESK (and hTRESK) were not sensitive to the polycation (less than 10 % 
inhibition, Fig. 1. E). 
 
 
Aspartate 135 (D135) in the extracellular ion pathway (EIP) of TREK-2 is responsible for 
the inhibition by ruthenium red 
 
Since the RR-sensitivity of TREK-2 is reported for the first time, we analyzed this inhibitory 
effect in more detail. RR inhibited TREK-2 with a half-maximal inhibitory concentration of 0.23 
± 0.06 µM (Fig. 2). Hill coefficient was 1.2 ± 0.3, suggesting that a single RR molecule 
interacted with the functional dimer. The rapid onset of the inhibition (Fig. 1. C) suggested that 
the RR-binding site of TREK-2 is extracellular, in good accordance with the limited permeation 
of the polycationic compound through the plasma membrane. 
In order to identify the amino acids interacting with the RR molecule, we mutated negatively 
charged and histidine residues of TREK-2 in the first extracellular loop, where the sequence of 
TREK-2 differed from the RR-resistant TREK-1 (Fig. 3. A). We changed these amino acids in 
combinations or one-by-one to the corresponding residues of TREK-1, and tested the sensitivity 
of the constructs to 10 µM RR (Fig. 3. B and C). D115Q, H130Q and E108Q-E111T double 
mutants were inhibited by RR, similarly to the wild type channel. In sharp contrast, the D133A-
D135I double mutant was resistant to the inhibitor. (Mouse TREK-2c was used (Mirkovic and 
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Wickman, 2011); the ALDADNA sequence is also conserved in other splice variants.) Next, we 
examined the individual contribution of D133 and D135 to the inhibitory effect. The D133A 
construct was similarly sensitive to RR as the wild type channel, but RR did not inhibit the D135I 
mutant (Fig. 3. B and C). Thus D135 is the major determinant of the inhibition of TREK-2 by 
RR.  
Since K2P channels function as dimers, we examined whether D135 of both subunits were 
necessary for the inhibition. We designed a tandem (concatenated) construct and expressed the 
two TREK-2 subunits as a continuous polypeptide (Fig. 3. D). Tandem TREK-2 was similarly 
sensitive to RR as the wild type channel (81.8 ± 3.1 % inhibition, n = 6, Fig. 3. D). Mutation of 
D135 in the N- or C-terminal half of the tandem construct reduced the sensitivity to RR (34.7 ± 
3.1 % (n = 6) and 48.2 ± 5.9 % (n = 6) inhibition for wt/D135I and D135I/wt channels by 10 µM 
RR, respectively, Fig. 3. D). Thus the D135 residues of both subunits contribute to the effect, 
although one intact D135 still allowed the inhibition by RR to some extent. 
As discussed above, TREK-1 is resistant to RR (Fig. 1. B and E). Because TREK-1 has 
isoleucine (I110) in the position corresponding to D135 of TREK-2, we replaced this 
hydrophobic residue with the acidic aspartate. As opposed to the wild-type channel, the I110D 
point mutant of TREK-1 was substantially inhibited by 10 µM RR (79.5 ± 1.7 % inhibition (n = 
6); Fig. 3. E). The introduction of the aspartate to the appropriate position was sufficient to create 
a RR binding site even in the molecular context of TREK-1. 
 
 
Ruthenium violet inhibits TRAAK more potently than RR 
 
Mouse TRAAK appeared to be less inhibited by RR in this study than we previously reported 
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(Czirják and Enyedi, 2002a). An old commercial preparation of RR (Sigma 1996) evoked 
qualitatively different effect on TRAAK from that of our present RR batch (Sigma 2013, Fig. 4). 
In addition to the higher efficacy of RR1996, the old product also inhibited TRAAK with slower 
kinetics than the new one. Mouse TRAAK was more efficiently inhibited by both RR 
preparations than the human ortholog, however, the slow kinetics of inhibition by RR1996 was 
apparent irrespective of the species (Fig. 4). 
It is known that commercial preparations of RR may contain contaminants, e.g. ruthenium 
ammine compounds (with absorption maxima between 200 and 400 nm), and ruthenium violet 
(RV, absorption peaks at 734 and 900 nm, see ref. (Luft, 1971)). In the absorption spectra of 
equal mass concentration of RR1996 and RR2013, the peak amplitudes at 533 nm, characteristic for 
RR, were different (Fig. 5. A). RR1996 preparation contained less ruthenium red than RR2013, 
despite of the more pronounced inhibition of TRAAK by the older preparation. Therefore we 
concluded that contaminants in the RR1996 sample also inhibit TRAAK in addition to RR. (Where 
not specified otherwise, RR2013 of high purity was used throughout this study.) 
Since a small absorption peak at 734 nm was present in RR1996 but not in RR2013 (Fig. 5. A), 
we examined whether ruthenium violet (RV, [Ru3N2(NH3)8(OH)(OH2)5]Cl5) inhibits TRAAK 
(Hall and Griffith, 1980). To this end, we purified RV by ion exchange chromatography using a 
low charge density CM-cellulose column (see Methods, and Fig. 5.A for the spectrum of purified 
RV). Ruthenium violet inhibited TRAAK with higher potency than ruthenium red (IC50 value of 
0.11 ± 0.01 and 1.7 ± 0.1 µM for RV and RR(2013), respectively, Fig. 5. B). Hill coefficients for 
RR and RV were 1.1 ± 0.1 and 2.0 ± 0.3, respectively, suggesting that the mechanisms of action 
of the two ruthenium compounds on TRAAK are different. TRAAK dimer may contain two 
binding sites for RV, but only one for RR. Reconstitution of the absorption maxima of RR1996 at 
533 and 734 nm by mixing RR2013 with purified RV indicated that RV was partly responsible for 
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the difference of inhibition of mTRAAK by the two RR preparations (see supplementary 
material). Our results suggest that RV is a more potent inhibitor of TRAAK than RR, and the 
effect of some commercial preparations of RR may also depend on their RV contamination in 
addition to their RR content. 
The effect of RV was also tested on a more extensive set of K2P channels (Fig. 5. C). The 
inhibitory profiles of RR (Fig. 1. E) and RV (Fig. 5. C) turned out to be similar. The D135I 
mutation also prevented the inhibitory effect of RV (Fig. 5. C), suggesting a common site of 
action of RR and RV in the case of TREK-2 channel. 
 
 
RR-sensitive background potassium current in DRG neurons 
 
Dorsal root ganglion (DRG) neurons have been reported to express predominantly TREK-2 
and the RR-insensitive TREK-1 and TRESK background K
+
 channels in rodents (Talley et al., 
2001; Kang and Kim, 2006; Dobler et al., 2007). We performed whole cell patch clamp 
recordings on mouse DRG neurons at 37 °C to investigate the RR-sensitive and temperature-
dependent TREK-2 current (Kang et al., 2005; Pereira et al., 2014). In a representative neuron, 
RR (10 µM) inhibited the K
+
 current by 71 % at -100 mV in 30 mM extracellular [K
+
], and the 
outward current was also reduced at positive potentials in accordance with the leak characteristics 
of the blocked current component (Fig. 6. A-C; voltage-gated K
+
 channels dominated the outward 
current). High sensitivity to RR is compatible with the predominant contribution of TREK-2 to 
the background potassium current in this neuron. (The reversal potential of the difference current 
(Fig. 6. B) closely approximates the calculated equlibrium potential of K
+
 (-40 mV in 30 mM 
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[K
+
] at 37 °C). RR also inhibited a small voltage-dependent component (between -60 and -40 
mV), the ion selectivity of which has not been further examined. The saturation effect of the 
difference current above +20 mV may be related to the voltage-dependent nature of the inhibition 
by the cationic dye.) 
We examined RR-sensitivity of the K
+
 currents of 20 DRG neurons with diameters in the 
range of 16-45 µm. The amplitudes of the K
+
 currents (the differences of inward currents in 2 and 
30 mM extracellular [K
+
] at -100 mV) were between 120 and 2540 pA. The effect of RR varied 
considerably in this cell p pulation, from complete insensitivity to about 75 % inhibition (Fig. 6. 
D). We found weak negative correlation between the K
+
 current amplitude and the RR-sensitivity 
(r =-0.6, p<0.005), suggesting that neurons with large K
+
 current at -100 mV expressed relatively 
less TREK-2.   
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DISCUSSION 
 
K2P background K
+
 channels are the major determinants and regulators of the resting 
membrane potential in several cell types (Enyedi and Czirják, 2010). However, the 
pharmacological separation of their almost identical macroscopic currents have not yet been 
adequately resolved.  In the absence of specific inhibitors, the pharmacological tools aiding the 
discrimination of the currents of different K2P channels are appreciated. This explains that the 
otherwise relatively non-specific ruthenium red (RR) has been extensively used to distinguish 
between TASK-1 and TASK-3 currents. 
In the present study we demonstrate that RR also discriminates between TREK-1 and TREK-
2 channels. In fact, this finding is so counter-intuitive that in a recent report, the RR-insensitivity 
of TREK-2 has been anticipated because TREK-1 is not affected by the compound (Cadaveira-
Mosquera et al., 2011). However, RR can distinguish between target proteins depending on a 
single amino acid difference (per subunit), and such a decisive variation of sequence is present 
not only in the TASK channels but also in the two closely related members of the TREK 
subfamily. The negatively charged aspartate 135 mediates th  inhibition of TREK-2 by RR, in 
sharp contrast to the RR-resistant TREK-1 containing the hydrophobic isoleucine 110 in the 
corresponding position. 
The outer entrance of the ion conducting pore of K2P channels is covered by an extracellular 
cap domain, as recently revealed by the crystal structures of TWIK-1 (PDB ID: 3UKM; (Miller 
and Long, 2012)), TRAAK (PDB ID: 3UM7 and 4I9W; (Brohawn et al., 2012; Brohawn et al., 
2013)), and TREK-2 (PDB ID: 4BW5). A short tunnel piercing through the extracellular cap, 
roughly parallel to the plane of the plasma membrane, the so-called extracellular ion pathway 
(EIP) connects the extracellular space to the pore entrance. (The EIP and the pore together form a 
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T shape, where the horizontal line of the “T” is the EIP, whereas the vertical line corresponds to 
the pore through the plasma membrane.) D135 residues are located in the middle of the EIP, on 
the ceiling of the tunnel, just above the selectivity filter, in symmetrical arrangement (Fig. 7). We 
propose that this junction region between the EIP and the pore entrance is the binding site of RR, 
where the inhibitor can electrostatically and/or sterically hinder the movement of the charge 
carrier. D135 residue, identified in the present study, is located at a position of the EIP that is 
similar, or maybe even, identical to E70 of TASK-3 (Czirják and Enyedi, 2003; Gonzalez et al., 
2013). The exact position of D135 of TREK-2 and E70 of TASK-3 relative to the EIP appears to 
be slightly different (compare Fig. 7 to Fig. 1 in the Gonzalez et al., 2013 reference), however, it 
remains a question how faithfully the static structure distorted into a protein crystal represents the 
fine details of side chain arrangements in the functional channels. The conditions of 
crystallization may have drastic effects on the conformation of K2P channels as exemplified by 
the different reported structures of TRAAK (Brohawn et al., 2012; Brohawn et al., 2013).  
TREK channels are regulated in a highly complex manner, and most of the regulatory 
properties are shared by TREK-1 and TREK-2. Both channels are mechanosensitive, 
temperature-dependent, activated by intracellular acidification, volatile anesthetics and 
polyunsaturated fatty acids, and inhibited by protein kinase A, C and AMP-activated protein 
kinase (Enyedi and Czirják, 2010). Although most properties of TREK-1 and TREK-2 are 
identical, some differences between them have also been reported. Extracellular acidification 
inhibits TREK-1, but activates TREK-2, depending on the protonation of a conserved histidine 
residue in the first extracellular loop of the channels (Sandoz et al., 2009; Bagriantsev et al., 
2011). The two TREK channels can also be distinguished on the basis of their different single-
channel conductance, however, this approach is complicated by the multiple conductance levels 
arising from alternative translation initiation variants (Thomas et al., 2008; Simkin et al., 2008). 
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TREK-1 and TREK-2 are differentially expressed in the central nervous system and also at the 
periphery, suggesting that the two apparently similar channel types may have different functions 
(for review, see (Noel et al., 2011)). Ruthenium red distinguishes between the macroscopic 
currents of TREK-1 and TREK-2, and may complement the presently available methodological 
repertoire for the discrimination of the two channel types. 
Ruthenium red also inhibits the third member of the TREK subfamily, TRAAK, although less 
efficiently than we originally reported (Czirják and Enyedi, 2002a). Despite of its lower pure RR 
content, RR1996 preparation was a more effective inhibitor of TRAAK than RR2013. Ruthenium 
violet (RV) also contributed to the inhibition of TRAAK by the old preparation. The different 
Hill coefficients for RR and RV suggest that not only their affinities to TRAAK but also the 
mechanisms of action of the two ruthenium compounds are different. It is probable that RR and 
RV also inhibit TRAAK by binding to negatively charged extracellular regions of the channel, 
however, the identification of these binding sites is not straightforward. Mouse TRAAK subunit 
contains 14 negatively charged (Asp and Glu) and 5 histidine (His) residues in its extracellular 
loops. The sequence alignments of TRAAK with the TREK channels and the crystal structures 
are not particularly helpful for the prediction of the regions responsible for the interaction. 
Therefore a comprehensive mutational screening approach will be required in the future to 
determine which amino acids constitute the RR and RV binding sites of TRAAK. 
Dorsal root ganglion (DRG) neurons express several K2P channel types, as detected by in situ 
hybridization (Talley et al., 2001). The contribution of different channels to the ensemble 
background K
+
 current was estimated by single channel analysis (Kang and Kim, 2006). TREK-2 
was suggested to contribute 69 % to the background K
+
 current at 37 °C, followed by TRESK (16 
%), TREK-1 (12 %), and TRAAK (3 %). In a recent report, TREK-2 was immunodetected in a 
high number of DRG neurons, and small DRG neurons were found to contain higher TREK-2 
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immunoreactivity than the large cells (Acosta et al., 2014). 
We were curious whether we can detect the ruthenium red sensitive TREK-2 current 
component by whole-cell patch clamp measurements in isolated DRG neurons. In several cells, 
characterized by relatively small (< 0.5 nA) K
+
 current amplitudes at -100 mV in high (30 mM) 
[K
+
], RR inhibited the current by 60-70 %. This strong inhibition by RR is consistent with high 
TREK-2 expression, and is in good accordance with the previous immunocytochemistry data that 
small cells express TREK-2 most abundantly (Acosta et al., 2014). Evidently, TRAAK and 
TASK-3 may have also contributed to the current inhibited by RR, although previous reports 
suggest that TREK-2 is predominant. On the other hand, in some neurons, characterized by 
relatively large (> 0.5 nA) K
+
 current amplitudes, the background potassium current was weakly 
(< 20 %) inhibited by RR, indicating that in these cells TREK-2 (as well as TRAAK and TASK-
3) were minor components. In summary, we provided the first data about the contribution of 
TREK-2 to the whole-cell background potassium current of individual DRG neurons, and our 
results suggest that ruthenium red can also be applied for the verification of TREK-2 current in 
other native cell types.  
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LEGEND TO FIGURES 
 
Fig. 1. TREK-2, TRAAK and TASK-3 are blocked by ruthenium red. 
A. Chemical structure and molecular formula of ruthenium red (RR). B. Representative two-
electrode voltage clamp recording from a Xenopus oocyte expressing mouse TREK-1. After the 
rundown of TREK-1 current at the beginning of the measurement, two ruthenium red 
preparations were administered (RR2013 and RR1996 from Sigma, as indicated by the colored 
horizontal bars). TREK-1 has not been affected by ruthenium red (10 µM). The current was 
measured at -100 mV and the extracellular [K
+
] was changed from 2 to 80 mM and back as 
shown above the recording. C. The sensitivity of mouse TREK-2 channel to ruthenium red 
(RR2013) was tested as in panel A. Ruthenium red (10 µM) strongly inhibited TREK-2 current. D. 
Representative recording of mouse TRAAK current inhibition by RR2013 (10 µM). The inhibition 
of TRAAK was intermediate between TREK-1 and TREK-2. E. Ruthenium red sensitivity of 
K2P channels (as indicated below the column graph) is illustrated. In addition to the positive 
control mouse TASK-3 (mTASK-3), human and mouse TREK-2 (hTREK-2 and mTREK-2) 
currents were also diminished by RR, whereas human and mouse TRAAK currents were less 
inhibited. TREK-1, TALK-1, TASK-1, TASK-2, THIK-1 and TRESK were not affected by RR. 
(Where not specified otherwise, RR2013 of high purity was used in the experiments. All oocyte 
measurements were performed at room temperature (21 °C).) 
 
Fig. 2. Dose-response relationship of TREK-2 current and ruthenium red concentration. 
Mouse TREK-2 currents were measured in high (80 mM) [K
+
] at -100 mV in the presence of 
different (0.03, 0.1, 0.3, 1, 3 and 10 µM) concentrations of ruthenium red. The currents were 
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corrected for the small nonspecific leak in 2 mM extracellular [K
+
] and normalized to the value 
without the inhibitor. Each data point represents the average of normalized currents of six to nine 
oocytes. The data points were fitted by a modified Hill equation (see Methods). 
 
Fig. 3. Mutation of aspartate 135 (D135) to isoleucine eliminates RR-sensitivity of TREK-2, 
whereas the substitution of isoleucin 110 (I110) in TREK-1 with aspartate confers RR-
sensitivity to the channel. 
A. Sequence alignment of a region of different K2P channels (as indicated on the left) between 
the first transmembrane segment and the first pore domain. In this region, TREK-2 contains 
additional negatively charged or histidine residues, compared to TREK-1 (as indicated with 
yellow and green). D135 residue of TREK-2, corresponding to the RR-binding E70 amino acid of 
TASK-3, is indicated with red and cyan. B. Represenative recordings of mouse wild type (wt), 
D135I and D133A mutant TREK-2 currents and their sensitivity to RR were measured similarly 
as in panel C of Fig. 1. C. Sensitivity of wild type (wt) and different mutant versions of mouse 
TREK-2 (as indicated below the column diagram) to ruthenium red (10 µM). Negatively charged 
and histidine amino acids of TREK-2 were replaced by the corresponding (non-conserved) 
residues of the RR-resistant TREK-1. The current in the presence of RR was normalized to the 
initial value without the inhibitor. D133A-D135I double and D135I point mutations completely 
prevented the inhibition of TREK-2 by RR (ANOVA, Scheffe’s post hoc test, p<10
-5
). The effect 
of the other mutations was not significant. (The numbers in the columns indicate the number of 
the measured oocytes.) D. The two subunits of TREK-2 dimer were expressed as a tandem 
construct (consisting of a single polypeptide chain), as indicated in the scheme illustrating 
transmembrane topology. Mutation of D135 in the upstream (D135I/wt, blue) or downstream 
(wt/D135I, red,) TREK-2 coding sequence reduced the inhibition by RR compared to the 
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construct composed of the wild type sequences (wt/wt, green, p<0.001). E. Normalized currents 
of wild type (wt), A108D-I110D double and I110D point mutant TREK-1 in the presence of RR 
(10 µM). 
 
Fig. 4. Inhibition of TRAAK by different commercial preparations of ruthenium red. 
A. Normalized currents of human and mouse TRAAK are plotted in the presence of different 
concentrations of RR purchased from Sigma in 2013. B. Similar measurement with an old RR 
preparation (Sigma 1996). Note the strong inhibition developing with slow kinetics. C. Dose-
response relationships of TRAAK current (human (hTRAAK, blue symbols) or mouse (mTRAAK, 
red symbols)) and ruthenium red concentration (RR1996 or RR2013, as indicated on the right) was 
calculated from the measurements in panel A and B, and fitted with the modified Hill equation 
(see Methods).  
 
Fig. 5. Ruthenium violet inhibits TRAAK more pot ntly than ruthenium red. 
A. Absorption spectra of equal mass (w/v) concentration of ruthenium red purchased from Sigma 
in 1996 (RR1996) or in 2013 (RR2013), and our purified ruth nium violet preparation (RV). B. 
Dose-response relationship of mouse TRAAK current and RR(2013) or RV. C. Sensitivity of 
different K2P channels (as indicated below the column graph) to RV (1 µM) was measured. 
TASK-3, TREK-2 and mouse TRAAK were strongly inhibited. The D135I mutation of TREK-2 
(D135I column) completely eliminated the sensitivity to RV. 
 
Fig. 6. RR-sensitive background potassium current in DRG neurons 
A. Representative current-voltage (I-V) relationships from a mouse DRG neuron. Currents were 
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measured in 2 mM (black curve) or 30 mM extracellular [K
+
] in the absence (blue) or presence 
(magenta) of RR (10 µM) using a voltage protocol consisting of a step to -100 mV for 200 ms 
from a holding potential of -80 mV, followed by a 600 ms ramp to +60 mV. The I-V relationships 
were plotted from the ramp data. B. The difference current inhibited by RR in the presence of 30 
mM [K
+
] is calculated from the data shown in panel A (by subtracting the magenta curve from 
the blue one). C. Currents at -100 mV of the same DRG neuron as in panel A were plotted as the 
function of time. The currents measured during the voltage step to -100 mV are shown in the 
inset. D. Correlation between the K
+
 current amplitude and the RR-sensitivity for 20 DRG 
neurons. The regression line (red solid) and 95 % confidence band (red dotted curves) of 
Pearson's correlation analysis are indicated. All DRG measurements were performed at 37 °C. 
 
Fig. 7. Aspartate 135 residues are positioned in the extracellular ion pathway (EIP) above 
the selectivity filter. 
The EIP tunnel is filled with a series of blue spheres in this schematic representation of human 
TREK-2 crystal structure (PDB ID: 4BW5, unpublished result of Pike ACW, et al.). K
+
 ions in 
the vertical channel pore are illustrated with four solid (tan) spheres below the EIP. Aspartate 135 
(D135) residues (yellow ball and stick representation, with red oxygen and blue nitrogen atoms) 
are located on the ceiling of the EIP above the selectivity filter. The two subunits are drawn as 
red and green ribbons. The view is not exactly perpendicular to the direction of the EIP, but the 
structure is slightly rotated around the vertical axis, in order to avoid the overlap of the D135 
residues of the two subunits. The NSSN and NSSNNS sequences of the subunits, respectively, 
are not resolved by the crystal structure, however, this does not affect the EIP. The graphics were 
produced with MolAxis (Yaffe et al., 2008) and VMD (Humphrey et al., 1996) software.  
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